Fight­ing for a place in the ul­cer­a­tive col­i­tis mar­ket, Sub­lim­i­ty rais­es $64M for an al­ter­na­tive drug to an­ti-TNF

The race to re­place an­ti-TNF in­jecta­bles in ul­cer­a­tive col­i­tis has just seen a new par­tic­i­pant in Sub­lim­i­ty Ther­a­peu­tics, pow­ered with $64 mil­lion it just raised from Or­bimed and Lon­gi­tude Cap­i­tal.

At the cen­ter of at­ten­tion is STI-0529, an oral for­mu­la­tion of drug called cy­closporine, which is ap­proved for sev­er­al in­flam­ma­to­ry dis­eases in­clud­ing rheuma­toid arthri­tis and pso­ri­a­sis (and of­ten used off-la­bel for Crohn’s dis­ease). The new funds will fu­el a Phase IIb study eval­u­at­ing the drug’s safe­ty and ef­fi­ca­cy in pa­tients with mod­er­ate to se­vere ul­cer­a­tive col­i­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER